ClinicalTrials.gov
ClinicalTrials.gov Menu

Implant-Abutment Interface Design on Bone and Soft Tissue Levels Around Implants Placed Using Different Transcrestal Sinus Floor Elevation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02953392
Recruitment Status : Recruiting
First Posted : November 2, 2016
Last Update Posted : August 28, 2018
Sponsor:
Information provided by (Responsible Party):
Ismael Khouly, NYU College of Dentistry

Brief Summary:
Sixty patients with partially edentulous posterior maxilla requiring a transcrestal sinus floor elevation technique to insert one implant will be selected. The purpose of this multi-center, prospective, double blind, and randomized investigation is to analyze a platform switched implant when placed at limited maxillary residual bone height with low bone density compared to a platform matching implant with or without bone graft material.

Condition or disease Intervention/treatment Phase
Tooth Loss Device: Anorganic Bovine Bone Graft Material Device: Collagen Membrane Device: Shelta Platform Switching Premium Implants Device: Shelta Platform Matching Premium Implants Not Applicable

Detailed Description:

Approximately 60 subjects who require at least one posterior maxilla implant in the areas of the second pre-molars or (first or second) molars with 6 to 9 mm of crestal bone below the sinus floor, as determined on the computerized axial tomographic (CT) scan, will be recruited for the study. Subjects will receive dental implants to replace a missing tooth (second pre-molar or first/second molar) on one side of the maxillary arch. Each subject will receive one type of implant: platform switched (PS) or platform matching (PM). Each site will receive either a bone graft material composed of anorganic bovine bone mineralized (ABBM, Bio-Oss, Geistlich Pharma) or no graft material (collagen membrane used for wound healing (Collatape, Zimmer)). At implant placement surgery and post-surgical follow-ups, the treated site will be examined, clinically measured, and radiographs and photographs will be taken.

The central hypothesis is that the mean crestal bone level for the platform switched (test implants) implants will be superior to the mean crestal bone level for the platform matching (control implants) implants when placed in limited maxillary residual bone in the posterior regions, regardless of the use of bone graft material or collagen membrane.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of Implant-Abutment Interface Design on Bone and Soft Tissue Levels Around Implants Placed Using Two Different Transcrestal Sinus Floor Elevation Approaches: A Multi-Center, Double Blind, Randomized Trial
Actual Study Start Date : May 10, 2016
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : May 2020

Arm Intervention/treatment
Active Comparator: Arm 1
Transcrestal Sinus Floor Elevation using platform switched implant with bone graft material.
Device: Anorganic Bovine Bone Graft Material
Anorganic bovine bone graft material is intended for augmentation or reconstructive treatment of the alveolar ridge, filling periodontal defects, filling defects after root resection, apicoectomy, and cystectomy, filling extraction sockets to enhance preservation of the alveolar ridge, and elevation of maxillary sinus floor.

Device: Shelta Platform Switching Premium Implants
Shelta implant systems are intended for immediate placement and function on single tooth and/or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.

Active Comparator: Arm 2
Transcrestal Sinus Floor Elevation using platform switched implant with no bone graft material.
Device: Collagen Membrane
Collagen dental wound dressing is intended for the management of oral wounds and sores, including; dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites, surgical wounds, and traumatic wounds.

Device: Shelta Platform Switching Premium Implants
Shelta implant systems are intended for immediate placement and function on single tooth and/or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.

Active Comparator: Arm 3
Transcrestal Sinus Floor Elevation using platform matching implant with bone graft material.
Device: Anorganic Bovine Bone Graft Material
Anorganic bovine bone graft material is intended for augmentation or reconstructive treatment of the alveolar ridge, filling periodontal defects, filling defects after root resection, apicoectomy, and cystectomy, filling extraction sockets to enhance preservation of the alveolar ridge, and elevation of maxillary sinus floor.

Device: Shelta Platform Matching Premium Implants
Shelta implant systems are intended for immediate placement and function on single tooth and /or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.

Active Comparator: Arm 4
Transcrestal Sinus Floor Elevation using platform matching implant with no bone graft material.
Device: Collagen Membrane
Collagen dental wound dressing is intended for the management of oral wounds and sores, including; dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites, surgical wounds, and traumatic wounds.

Device: Shelta Platform Matching Premium Implants
Shelta implant systems are intended for immediate placement and function on single tooth and /or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.




Primary Outcome Measures :
  1. Mean crestal bone level changes measured in mm using periapical radiographs and CT scans. [ Time Frame: 12 months ]
    Mean crestal bone level change around the implants will be determined by periapical radiographs of mesial and distal bone levels. CT scans will be used to determine buccal and lingual bone level change between implant placement and 12 months, following placement of a platform switched implants or platform matching implants.

  2. Mean periapical sinus bone level changes measured in mm using periapical radiographs and CT scans. [ Time Frame: 12 months ]
    Mean periapical sinus bone level change between implant placement and 12 months will be determined by radiographic measurement (using periapical radiographs and CT scans) following placement of a platform switched implant or platform matching implant in the posterior region of the maxilla, with bone graft material or without bone graft material.

  3. Implant survival measured through observation. [ Time Frame: 12 months ]
    Implant survival will be measured at implant loading and 12 months following implant placement will be assessed through clinical observation.

  4. Implant success rate measured by percentage. [ Time Frame: 12 months ]
    Implant success rate will be assessed at implant loading and 12 months following implant placement measured by percentage.


Secondary Outcome Measures :
  1. Crestal bone height changes measured in mm using periapical radiographs. [ Time Frame: 12 months ]
    Additional crestal bone height change determined by measurements of periapical radiographs of mesial and distal bone levels between implant placement and implant loading, and between implant loading and 12 months post-implant placement.

  2. Implant Stability Quotient (ISQ) measured in N/cm. [ Time Frame: 6 months ]
    Implant Stability Quotient (ISQ) between implant placement and implant loading and at 6 months and between implant loading.

  3. Periodontal Pocket Depths measured in mm. [ Time Frame: 12 months ]
    Periodontal Pocket Depths assessed at screening, implant loading, and 12 months post-implant placement.

  4. Subject satisfaction assessed through questionnaire. [ Time Frame: 12 months ]
    Subject satisfaction at implant placement, immediate post-operative, and 12 months post-implant placement.

  5. Changes in sinus anatomy measured in mm compared to implant survival. [ Time Frame: 12 months ]
    Changes in the sinus anatomy measured in mm compared to implant survival.

  6. Changes in sinus anatomy measured in mm compared to implant success. [ Time Frame: 12 months ]
    Changes in the sinus anatomy measured in mm compared to implant success.

  7. Changes in sinus anatomy measured in mm compared to crestal bone changes. [ Time Frame: 12 months ]
    Changes in the sinus anatomy measured in mm compared to crestal bone level changes. implant stability (ISQ).

  8. Changes in sinus anatomy measured in mm compared to implant stability. [ Time Frame: 12 months ]
    Changes in the sinus anatomy measured in mm compared to implant stability (ISQ).

  9. Changes residual crestal bone height measured in mm compared to implant survival. [ Time Frame: 12 months ]
    Changes in residual crestal bone height compared to implant survival.

  10. Changes residual crestal bone height measured in mm compared to implant success. [ Time Frame: 12 months ]
    Changes in residual crestal bone height compared to implant success.

  11. Changes residual crestal bone height measured in mm compared to implant stability. [ Time Frame: 12 months ]
    Changes in residual crestal bone height compared to implant stability (ISQ).

  12. Changes residual crestal bone height measured in mm compaierd to sinus bone levels. [ Time Frame: 12 months ]
    Changes in residual crestal bone height compared to sinus bone levels.

  13. Bleeding on probing measured by present or not present. [ Time Frame: 12 months ]
    Bleeding on probing assessed at screening, implant loading, and 12 months post-implant placement.

  14. Gingival Recession measured in mm. [ Time Frame: 12 months ]
    Gingival recession assessed at screening, implant loading, and 12 months post-implant placement.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subjects must have read, understood and signed an informed consent form.
  2. Subjects must be 18 to 70 years of age.
  3. Subjects must be able and willing to follow study procedures and instructions.
  4. Subject must maintain good oral hygiene.
  5. Subjects must have a single tooth missing in the pre-molar or molar region of the maxilla (ADA tooth positions 2-4 and 13-15; FDI tooth positions 15-17 and 25-27).
  6. The mesio-distal distance of the tooth gap at bone level must be at least 6.8 mm to allow for placement of the Ø3.8 mm implant with a minimal distance of 1.5 mm from the implant shoulder to the adjacent tooth at bone level. A minimum of 7.8 mm of buccal-lingual ridge to allow 2 mm of buccal and lingual plate will be required.
  7. No apical disorder/inflammation at the area of the implant site.
  8. Residual bone height ranging from 6 to 9 mm.
  9. The implant must penetrate at least 2 mm into the sinus on the mesial or distal sides.
  10. Sufficient bone width in the edentulous region (≥ 6mm).
  11. Subjects must be committed to the study and attend the required follow-up visits.

Exclusion Criteria:

  1. Subjects with a systemic disease that would preclude dental implant surgery (e.g. serious internal medical problems, disorders of bone metabolism, uncontrolled bleeding disorders, weakened immune system, illness requiring periodic use of steroids, uncontrollable endocrine disorders, uncontrolled diabetes).
  2. Subjects who have failed to maintain good plaque control.
  3. Subjects with any contraindications for oral surgical procedures (e.g. inadequate wound healing capacity, poor oral hygiene, maxillary and mandibular growth not completed, xerostomia).
  4. Subjects with mucosal diseases (e.g., erosive lichen planus) in the localized area around the study implant site.
  5. Subjects presenting with maxillary sinus pathology.
  6. Subjects with a history of local irradiation therapy in the head/neck region.
  7. Subjects with severe bruxing, parafunctional habits, or temporomandibular joint dysfunction.
  8. Subjects receiving, or having a history of receiving intravenous or subcutaneous antiresorptive agents associated with osteonecrosis of the jaw, such as bisphosphonates.
  9. Oblique sinus floor (> 45 inclination).
  10. Subjects with any untreated endodontic lesions or untreated periodontal disease.
  11. Subjects who are heavy smokers (defined as >10 cigarettes per day or >1 cigar per day) or chew tobacco, including within 3 months prior to enrollment.
  12. Subjects who have physical or mental handicaps that would interfere with the ability to perform adequate oral hygiene.
  13. Subjects who are pregnant or intending to become pregnant during the duration of the study.
  14. Subjects requiring bone augmentation or socket grafting prior to surgery.
  15. Subject allergic to collagen or porcine derived products.
  16. Subjects with conditions or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non- compliance or unreliability.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02953392


Contacts
Contact: Ismael E. Khouly, DDS, MS, PhD 212-998-9453 IEK3@nyu.edu

Locations
United States, New York
Bluestone Center for Clinical Research Recruiting
New York, New York, United States, 10010
Contact: Ismael E Khouly, DDS, MS, PhD    212-998-9453    IEK3@nyu.edu   
Sponsors and Collaborators
NYU College of Dentistry
Investigators
Principal Investigator: Ismael E Khouly, DDS, MS, PhD Bluestone Center for Clinical Research

Responsible Party: Ismael Khouly, Associate Director of Periodontology & Implant Dentistry, NYU College of Dentistry
ClinicalTrials.gov Identifier: NCT02953392     History of Changes
Other Study ID Numbers: 15-01349
First Posted: November 2, 2016    Key Record Dates
Last Update Posted: August 28, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Tooth Loss
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases
Tooth Diseases